◀ Back to PIK3R1
PIK3R1 — PRKCZ
Pathways - manually collected, often from reviews:
-
KEGG Insulin signaling pathway:
PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5
→
PRKCI/PRKCZ
(protein-protein, compound)
-
KEGG Type II diabetes mellitus:
PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5
→
PRKCZ
(protein-protein, indirect effect)
-
KEGG Chemokine signaling pathway:
PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5
→
PRKCZ
(protein-protein, activation)
-
NCI Pathway Database IL2 signaling events mediated by PI3K:
IL2/IL2R alpha/beta/gamma/JAK1/LCK/JAK3/SHC/GRB2/SOS1/GAB2/SHP2/PI3K complex (IL2RA-IL2RB-IL2RG-IL2-JAK1-LCK-JAK3-SHC1-GRB2-SOS1-GAB2-PTPN11-PIK3CA-PIK3R1)
→
PKC zeta (PRKCZ)
(modification, activates)
Gómez et al., Exp Cell Res 1995, Gómez et al., J Immunol 1997
Evidence: mutant phenotype, other species
-
NCI Pathway Database CXCR4-mediated signaling events:
PI3K Class I family (PIK3CA/PIK3R1/PIK3CB/PIK3R1/PIK3CG/PIK3R6)
→
PKC zeta (PRKCZ)
(modification, activates)
Petit et al., J Clin Invest 2005*, Chen et al., Mol Biol Cell 2008
Evidence: mutant phenotype, assay
-
NCI Pathway Database ErbB1 downstream signaling:
PI3K Class IA family (PIK3CA/PIK3R1/PIK3CB/PIK3R1)
→
PKC zeta (PRKCZ)
(modification, activates)
Romanelli et al., Mol Cell Biol 1999*, Corbit et al., Mol Cell Biol 2000*, Romanelli et al., J Biol Chem 2002*
Evidence: assay
-
WikiPathways Chemokine signaling pathway:
PIK3CA/PIK3CD/PIK3R1/PIK3R2/PIK3R3/PIK3CG/PIK3R5/PIK3CB
→
PRKCZ
(activation)
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
Text-mined interactions from Literome
Nguyen et al., Ann N Y Acad Sci 2005
:
Relaxin also stimulates
protein kinase C zeta (PKCzeta) translocation to the plasma membrane in a
PI3K dependent manner in THP-1 and MCF-7 cells
Esposito et al., Mol Pharmacol 2008
:
However, phosphoinositide dependent kinase-1, Akt/protein kinase B, and
protein kinase Czeta activities were rapidly induced after SR141716 treatment of L6 cells in a
PI3K dependent manner